VG2025

AXP000083.1 · Oncolytic virus

Platform
HSV-1 (ICP34.5- ICP47-)
Originator
Virogin Biotech
Sponsor
Virogin Biotech

Names

NameTypeSource
VG2025preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
ICP34.5 and ICP47 deleted
Transgenes
IL12A, IL12B, IL15, IL15RA
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C187035

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07682870A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid TumorsRecruitingPhase 1/22026-09-042028-12-0242Advanced Malignant Solid Tumor
NCT07522476A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic CholangiocarcinomaRecruitingPhase 22026-08-252028-01-1830Intrahepatic Cholangiocarcinoma
NCT07357220A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruitingPhase 1/22026-03-022027-02-2872Colorectal Cancer With Hepatic Metastases
NCT06365918Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With CarcinomatosisWithdrawnPhase 12024-09-302024-10-020Advanced Solid Tumor; Carcinomatosis
NCT05266612Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsUnknownPhase 12022-11-092024-12-3112Solid Tumor
NCT05477849A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid TumorsRecruitingPhase 12022-08-232025-10-3130Advanced Malignant Solid Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 36938544Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1.Molecular therapy oncolytics2023name in abstract: VG2025

Notes

Second Virogin oHSV: IL-12 and IL-15/IL-15Ralpha, without the PD-L1 blocking peptide of VG161; a distinct construct, so a separate program.

How to cite

VG2025 (AXP000083.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000083.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.